STOK
HEALTHCAREStoke Therapeutics Inc
$33.28+0.32 (+0.97%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving STOK Today?
No stock-specific AI insight has been generated for STOK yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$8.70$40.22
$33.28
Fundamentals
Market Cap$2.0B
P/E Ratio—
EPS$-0.12
Dividend Yield—
Dividend / Share—
ROE-0.0%
Profit Margin-0.0%
Debt / Equity—
Trading
Volume575K
Avg Volume (10D)—
Shares Outstanding59.2M
STOK News
20 articles- Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue EstimatesYahoo Finance·May 7, 2026
- Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business UpdatesYahoo Finance·May 7, 2026
- Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Lags Revenue EstimatesYahoo Finance·May 6, 2026
- Stoke Therapeutics to Host Webcast and Conference Call to Discuss First Quarter 2026 Business and Financial UpdatesYahoo Finance·Apr 30, 2026
- Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Yahoo Finance·Apr 16, 2026
- Zealand Pharma Appoints Eric Rojas as Vice President and Head of Investor RelationsYahoo Finance·Apr 14, 2026
- Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare ConferenceYahoo Finance·Apr 8, 2026
- Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of DirectorsYahoo Finance·Apr 7, 2026
- Stoke Therapeutics Auditor Switch Puts Biotech Governance In FocusYahoo Finance·Apr 6, 2026
- Biogen, on the heels of a $5.6B buyout, turns its sights to early-stage assetsBiopharmadive·Apr 1, 2026
- Stoke Therapeutics Stock Up 340% as Chair Sells $174K in SharesMotley Fool·Mar 28, 2026
- Stoke Therapeutics CMO Sells $457,000 in Stock Amid 300% RallyMotley Fool·Mar 24, 2026
- Biogen Rare Disease Data And Valuation Discount Draw Investor AttentionYahoo Finance·Mar 12, 2026
- Orchestra BioMed Holdings, Inc. (OBIO) Surpasses Q4 Earnings and Revenue EstimatesYahoo Finance·Mar 12, 2026
- Vertex (VRTX) Moves 8.3% Higher: Will This Strength Last?Yahoo Finance·Mar 11, 2026
- How Investors May Respond To Stoke Therapeutics (STOK) NEJM Data And 2027 FDA Filing TimelineYahoo Finance·Mar 6, 2026
- Dianthus Therapeutics, Inc. (DNTH) Stock Jumps 12.0%: Will It Continue to Soar?Yahoo Finance·Mar 5, 2026
- The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet SyndromeYahoo Finance·Mar 4, 2026
- These Growth Stocks Form Classic Cup Bases. Here's Where To Buy.Yahoo Finance·Feb 27, 2026
- Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care ConferenceYahoo Finance·Feb 24, 2026
All 20 articles loaded
Price Data
Open$34.49
Previous Close$32.96
Day High$35.24
Day Low$32.20
52 Week High$40.22
52 Week Low$8.70
52-Week Range
$8.70$40.22
$33.28
Fundamentals
Market Cap$2.0B
P/E Ratio—
EPS$-0.12
Dividend Yield—
Dividend / Share—
ROE-0.0%
Profit Margin-0.0%
Debt / Equity—
Trading
Volume575K
Avg Volume (10D)—
Shares Outstanding59.2M
About Stoke Therapeutics Inc
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops new antisense oligonucleotide (ASO) drugs to treat the underlying causes of serious genetic diseases in the United States. The company is headquartered in Bedford, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—